drugset / Trial / NCT02817906
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.
Timeline
- Start
- 2016-08-29
- Primary completion
- 2019-01-30
- Completion
- 2019-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lumateperone | Small molecule | 9 mg | — |
Indications
No indication recorded.